|
|
 Previous Article | Table of Contents | Next Article 
Hematologic effects of recombinant human granulocyte colony-stimulating
factor in patients with malignancy
A Lindemann, F Herrmann, W Oster, G Haffner, W Meyenburg, LM Souza and R Mertelsmann
Department of Hematology, University of Mainz, FRG.
The effect of recombinant human granulocyte colony-stimulating factor
(G-CSF) on hematologic parameters was evaluated in a phase I clinical study
in 18 patients with advanced malignancy. G-CSF was administered once daily
as a 30-minute infusion for 14 days; three patients each were treated at
increasing dose levels of 1, 3, 10, 30, and 60 micrograms kg-1 day-1. A
transient decrease in neutrophil and monocyte counts was observed
immediately after the G-CSF infusion, followed by a dose-dependent increase
of up to 15-fold. G-CSF-induced neutrophils exhibited an increased O2-
radical production, and serum levels of enzymes related to granulocyte
turnover, including lysozyme and elastase, were markedly elevated during
therapy. A dose-dependent depression of platelet counts occurred in the
second third of the treatment course, followed by a spontaneous recovery
despite continuing therapy. G-CSF was well-tolerated; minor to moderate
bone pain was the most common side effect. The primary course of the
malignant diseases studied was not significantly altered. G-CSF appears to
be an appropriate means to selectively increase the number of functionally
competent polymorphonuclear phagocytes.
Volume 74,
Issue 8,
pp. 2644-2651,
12/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. A. Velders, J. F. M. Pruijt, P. Verzaal, R. van Os, Y. van Kooyk, C. G. Figdor, E.-J. F. M. de Kruijf, R. Willemze, and W. E. Fibbe
Enhancement of G-CSF-induced stem cell mobilization by antibodies against the beta 2 integrins LFA-1 and Mac-1
Blood,
June 17, 2002;
100(1):
327 - 333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Calderwood, L. Kilpatrick, S. D. Douglas, M. Freedman, K. Smith-Whitley, M. Rolland, and J. Kurtzberg
Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b
Blood,
January 15, 2001;
97(2):
376 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Leavey, K. S. Sellins, G. Thurman, D. Elzi, A. Hiester, C. C. Silliman, G. Zerbe, J. J. Cohen, and D. R. Ambruso
In Vivo Treatment With Granulocyte Colony-Stimulating Factor Results in Divergent Effects on Neutrophil Functions Measured In Vitro
Blood,
December 1, 1998;
92(11):
4366 - 4374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Borgbjerg, D. Hovgaard, J. B. Laursen, and J. Aldershvile
Granulocyte colony stimulating factor in neutropenic patients with infective endocarditis
Heart,
January 1, 1998;
79(1):
93 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Baker and J. Levin
Transient Thrombocytopenia Produced by Administration of Macrophage Colony-Stimulating Factor: Investigations of the Mechanism
Blood,
January 1, 1998;
91(1):
89 - 99.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Freeman, Z. Quezado, F. Zeni, C. Natanson, R. L. Danner, S. Banks, M. Quezado, Y. Fitz, J. Bacher, and P. Q. Eichacker
rG-CSF reduces endotoxemia and improves survival during E. coli pneumonia
J Appl Physiol,
November 1, 1997;
83(5):
1467 - 1475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Neelis, S. C.C. Hartong, T. Egeland, G. R. Thomas, D. L. Eaton, and G. Wagemaker
The Efficacy of Single-Dose Administration of Thrombopoietin With Coadministration of Either Granulocyte/Macrophage or Granulocyte Colony-Stimulating Factor in Myelosuppressed Rhesus Monkeys
Blood,
October 1, 1997;
90(7):
2565 - 2573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, J. M. Boyett, W. T. Hughes, G. K. Rivera, M. L. Hancock, J. T. Sandlund, T. Synold, M. V. Relling, R. C. Ribeiro, W. M. Crist, et al.
Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
June 19, 1997;
336(25):
1781 - 1787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
